A Study in Second Line Metastatic Colorectal Cancer
Status:
Completed
Trial end date:
2016-06-20
Target enrollment:
Participant gender:
Summary
The purpose of this study is to compare overall survival in participants with metastatic
colorectal cancer treated with either ramucirumab and FOLFIRI or placebo and FOLFIRI.